Will this trial show a positive result on overall SurvivalOutcome measureOverall Survival (OS)Overall survival measures how long patients live after treatment starts. It is usually the hardest and most market-important oncology endpoint because it reflects direct patient benefit.ClinicalTrials.gov outcome?
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the
TLX597-Tx is a PSMA 1 -targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA 2 initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification.